Category list : All-Wales Medicines Strategy Group
Sort by: Newest first Oldest first A-Z Z-A
-
Restrictions on prescribing OTC treatments rejected in Wales Subscription
Proposals to restrict the prescribing of medicines and other treatments that are available over the counter will not go ahead in Wales.
-
Three-year PrEP pilot begins in Wales
A trial has begun in Wales to assess the use of the antiretroviral combination treatment emtricitabine/tenofovir disoproxil (marketed as Truvada) for pre-exposure prophylaxis (PrEP) against HIV infection.
-
Treatment fund launched in Wales for newly approved drugs
An £80m new treatment fund to pay for high-cost drugs approved for use on the NHS in Wales has been launched.
-
Welsh audit body recommends managing medicines plan
The government, the NHS and health bodies should revise the indicators used to compare how different prescribers and organisations use medicines, says a report by the Welsh Audit Office.
-
Gething confirms £80m fund for high-cost medicines in Wales
A central fund worth £80m that will pay for the immediate use of new, high-cost medicines that are approved for use in Wales has been announced by Vaughan Gething, cabinet secretary for health for the Welsh government.
-
Welsh Labour pledge to create £80m central fund for high cost drugs Subscription
Welsh Labour has pledged to create an £80m central fund to pay for high cost medicines if they retain control of the National Assembly for Wales following the election on 5 May 2016.
-
January 2016: AWMSG approvals Subscription
The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use by the NHS in Wales: atazanavir/cobicistat (Evotaz) for adults infected with human immunodeficiency virus-1 (HIV-1); efavirenz (Sustiva) for children aged between 3 months and 3 years who are infected with HIV-1; macitentan (Opsumit) for adults with pulmonary arterial hypertension (only where the approved patient access scheme is used); empagliflozin (Jardiance) for type 2 diabetes. Full details ...
-
December 2015: AWMSG approvals Subscription
The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use in NHS Wales: Cetuximab (Erbitux; Merck Serono) for the first-line treatment of epidermal growth factor receptor-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy or the chemotherapy regimen FOLFOX. Ivacaftor (Kalydeco; Vertex) for cystic fibrosis (CF) in patients aged 6 years and older who have mutations in the CF transmembrane ...
-
December 2015: AWSMG approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Abasaglar (a biosimilar of insulin glargine; Eli Lilly and Company) for diabetes mellitus in patients aged 2 years and above. Sucroferric oxyhydroxide (Velphoro; Vifor Fresenius Medical Care Renal Pharma) for controlling serum phosphorus levels in adults with chronic kidney disease who are on haemodialysis or peritoneal dialysis where non-calcium based ...
-
AWMSG November medicines approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Xultophy (insulin degludec and liraglutide) for use with oral antidiabetic drugs to treat adults with type 2 diabetes — it can only be used when oral treatments combined with basal insulin do not provide adequate glycaemic control; Fomicyt (fosfomycin) to treat acute osteomyelitis, complicated urinary tract infections, nosocomial lower respiratory tract infections or bacterial ...
Show 10 per page20 per page50 per page
